Results 11 to 20 of about 4,843 (156)

Economic expertise of alirocumab in standard lipid lowering therapy insusceptibility [PDF]

Качественная клиническая практика, 2018
Usage of PCSK9 inhibitors is a new approach of lipid lowering therapy allowing overcomes as well insusceptibility of standard statins’ therapy as their intolerance.
S. K. Zyryanov, I. N. Dyakov
doaj   +1 more source

PCSK9 Inhibitors Reduce Oxidative Stress Biomarkers in Heterozygous Familial Hypercholesterolemia. [PDF]

J Cell Mol Med
ABSTRACT Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, such as alirocumab and evolocumab, effectively reduce LDL‐C levels, improve cardiovascular outcomes, and are well tolerated in the treatment of heterozygous familial hypercholesterolemia (HeFH).
Woźniak-Szczepocka A, Pawlos A, Gorzelak-Pabiś P, Broncel M, Bukowska B, Woźniak E.   +5 more
europepmc   +2 more sources

Lipoprotein(a) and the Effect of Alirocumab on Revascularization Following Acute Coronary Syndrome. [PDF]

, 2023
BACKGROUND Many patients require revascularization after an index acute coronary syndrome (ACS). Lipoprotein(a) is thought to play a pathogenic role in atherothrombosis. In ODYSSEY OUTCOMES, alirocumab reduced major adverse cardiovascular events after
Islam, Shahidul, Goodman, Shaun G, Szarek, Michael, Kim, Sang-Hyun, Jukema, J. Wouter, Schwartz, Gregory G., Jukema, J Wouter, Harrington, Robert A, Goodman, Shaun G., Pordy, Robert, Morais, Joao, Diaz, Rafael, Bhatt, Deepak L., Zeiher, Andreas M, Bhatt, Deepak L, White, Harvey D, White, Harvey D., Schwartz, Gregory G, Steg, Ph. Gabriel, Bittner, Vera A., Steg, P Gabriel, Kim, Hyo-Soo, Steg, P. Gabriel, Scemama, Michel, Bittner, Vera A, Harrington, Robert A., Chiang, Chern-En, Zeiher, Andreas M., Gotcheva, Nina, Valgimigli, Marco   +29 more
core   +2 more sources

Transient injection site reaction to alirocumab during immune system activation: a case series. [PDF]

, 2022
Background Injection site reactions (ISRs) are known side effects of the proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor alirocumab. Transient ISR to alirocumab after a long phase of good tolerability have not been reported previously ...
Räber, Irene, Bär, Sarah, Schlapbach, Christoph, Koskinas, Konstantinos C, Räber, Lorenz, Koskinas, Konstantinos C.   +5 more
core   +2 more sources

Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE

Archives of Medical Science, 2021
Introduction The phase IIIb open-label ODYSSEY APPRISE study prospectively assessed the safety and efficacy of alirocumab (a proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitor) in a real-life setting in high cardiovascular risk patients with
Maciej Banach, José Luis López-Sendon, Maurizio Averna, Bertrand Cariou, Megan Loy, Garen Manvelian, Isabela Batsu, Yann Poulouin, Daniel Gaudet   +8 more
doaj   +1 more source

Effects of alirocumab on cardiovascular events and all-cause mortality: a systematic review and meta-analysis [PDF]

Reviews in Cardiovascular Medicine, 2021
Evaluation of the effects of alirocumab on cardiovascular (CV) events, CV mortality and all-cause mortality. Data search was carried out using the Cochrane Library, PubMed, Web of Science and Embase. The search time is up to November 18, 2020.
Wanting Wang, Zhaoqiang Feng, Jinghui Bai   +2 more
doaj   +1 more source

Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study [PDF]

The Korean Journal of Internal Medicine, 2019
Background/Aims Efficacy and safety data of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), is not yet well established in the Korean population.
Chang-Wook Nam, Dong-Soo Kim, Jianyong Li, Marie T. Baccara-Dinet, Ivy Li, Ji-Hyun Kim, Chong-Jin Kim   +6 more
doaj   +1 more source

Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Patients Receiving Maintenance Dialysis: The ALIrocumab in DIALysis Study (A Phase 3 Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen)Plain-Language Summary

Kidney Medicine, 2022
Rationale & Objective: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab is used in the general population to treat dyslipidemia, but little is known about the effects of alirocumab on lipid levels, biomarkers, the ...
Cara East, Kyle Bass, Ankit Mehta, Gelareh Rahimighazikalayed, Sandy Zurawski, Teodoro Bottiglieri   +5 more
doaj   +1 more source

Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat

Frontiers in Cardiovascular Medicine, 2022
AimsThe efficacy of anti-proprotein convertase subtilisin/Kexin type 9 (PCSK9) monoclonal antibodies in patients with atherosclerotic cardiovascular disease (ASCVD) remains unclear.
Hong-Fei Wang, Hong-Fei Wang, Yu-Cheng Mao, Yu-Cheng Mao, Xin-Yi Xu, Xin-Yi Xu, Si-Yu Zhao, Si-Yu Zhao, Dan-Dan Han, Dan-Dan Han, Shi-Yao Ge, Shi-Yao Ge, Kai Song, Kai Song, Chang Geng, Chang Geng, Qing-Bao Tian, Qing-Bao Tian   +17 more
doaj   +1 more source

Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials

Cancer Medicine, 2023
Objective Assess the risk of new and worsening cancer events among participants who received the lipid‐lowering therapy alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor. Design Pooled post hoc analysis. Setting Six phase 3 or phase 4
Kusha A. Mohammadi, Taylor Brackin, Gregory G. Schwartz, Philippe Gabriel Steg, Michael Szarek, Garen Manvelian, Robert Pordy, Sergio Fazio, Gregory P. Geba   +8 more
doaj   +1 more source